ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (Nasdaq: INHX) today announced that John J. Alam, M.D. has joined Inhibitex as its Senior Medical Advisor. Dr. Alam was formerly Executive Vice President, Medicines Development and Chief Medical Officer at Vertex Pharmaceuticals, Incorporated. Dr. Alam will be responsible for formulating and directing the clinical and regulatory strategies for Inhibitex’s development programs, including FV-100, which is in Phase II clinical development for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C infections (HCV).
